News and Announcements
Pelikin capital raise now live – 20% already secured
- Published September 09, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Pelikin has recently secured 20% of its current fundraising goal via single Australian based sophisticated investor.
The fintech startup is raising a minimum of A$2,000,000 to rapidly expand all facets for it’s business. Key areas of focus will be driving customer acquisition to achieve market fit in the Australian market, executing the product roadmap to broaden the Pelikin value proposition and New Zealand market entry along with investigations into other markets across Asia and North America.
With A$400,000 secured, Pelikin is determined to welcome additional value-adding investors to it’s team who share their vision of empowering young people to achieve their travel goals.
About Pelikin
Pelikin is a multi-currency free banking app and pre-paid Visa card for young travellers. It helps millennials spend, send and manage their cash money overseas, without bank fees or annoying red tape. After nailing down partnerships with Heritage Bank (ADI) and Visa, and following a successful global product beta , the Melbourne fintech is set to launch in Q4 2019.
Pelikin is currently raising A$2 million to boost customer acquisition and product development, with an eye on the NZ and US markets.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
